Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled study of inhaled GB002 in pulmonary arterial hypertension
MOH_2020-12-09_009533Phase 2Recruiting
- Sponsor
- GB002, Inc.
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing GB002 60 mg twice daily with Placebo twice daily (2 arms). Started Sep 2020; status: recruiting.
02
Drugs
seralutinib
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on MOH_2020-12-09_009533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2020-12-09_009533.